NCT04837677View on ClinicalTrials.gov

A Study of PRT1419 in Patients With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

August 11, 2021

Primary Completion Date

February 6, 2023

Study Completion Date

February 6, 2023

Conditions
SarcomaMelanomaLung CancerBreast CancerEsophageal CancerCervical CancerHead and Neck Cancer
Interventions
DRUG

PRT1419

PRT1419 will be administered by intravenous infusion

Trial Locations (7)

15232

UPMC Hillman Cancer Center, Pittsburgh

19107

Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia

32746

Florida Cancer Specialists, Lake Mary

34232

Florida Cancer Specialists, Sarasota

37203

Tennessee Oncology, Nashville

52242

University of Iowa Hospitals and Clinics, Iowa City

80218

Sarah Cannon Research Institute at HealthONE, Denver

Sponsors
All Listed Sponsors
lead

Prelude Therapeutics

INDUSTRY

NCT04837677 - A Study of PRT1419 in Patients With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter